Search Grant Opportunities

CDMRP Neurofibromatosis Clinical Trial Award

ID: HT942524NFRPCTA • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)

Description

The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

Background
The NFRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of NF. The vision of the FY24 NFRP is to decrease the clinical impact of neurofibromatosis (NF) by promoting research directed toward the understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis to enhance the quality of life for persons with these disorders that impact Service Members, Veterans, and the general public.

Grant Details
The NFRP seeks to support innovative, high-impact research that will foster new directions for and address neglected issues in NF research; sponsor multidisciplinary and multi-institutional collaborations; promote translational and clinical studies; and develop a balanced portfolio of meritorious research related to all aspects of NF type 1 (NF1), NF type 2 (NF2), and schwannomatosis. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

The NFRP Clinical Trial Award supports the rapid implementation of clinical trials designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged.

Eligibility Requirements
Eligible applicants include all investigators within the military services and those involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies. The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

Period of Performance
The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for studies regulated by the Regulatory Agency.

Grant Value
$25.0M is allocated for FY24 NFRP Clinical Trial Award.
Show All

Overview

Agency
U.S. Army Medical Research Acquisition Activity (USAMRAA) [DoD - USA - MEDCOM - MRDC]
Category of Funding
Science and Technology and other Research and Development
Funding Instruments
Cooperative Agreement
Grant
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
Grants.gov
On 6/26/24 U.S. Army Medical Research Acquisition Activity posted grant opportunity HT942524NFRPCTA for CDMRP Neurofibromatosis Clinical Trial Award with funding of $1.6 million. The grant will be issued under grant program 12.420 Military Medical Research and Development. It is expected that one grant will be made.

Timing

Posted Date
June 26, 2024, 12:00 a.m. EDT
Closing Date
Oct. 3, 2024, 12:00 a.m. EDT Past Due
Last Updated
June 26, 2024, 10:41 a.m. EDT
Version
1
Archive Date
Nov. 2, 2024

Eligibility

Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Award Sizing

Ceiling
Not Listed
Floor
Not Listed
Estimated Program Funding
$1,600,000
Estimated Number of Grants
1

Contacts

Contact
Ebony S Simmons Grantor
Contact Email
help@ebrap.org   Profile
Email Description
CDMRP Help Desk
Contact Phone
(301) 619-2105

Documents

Posted documents for HT942524NFRPCTA

Potential Applicants and Partners

Awardees that have recently won grants similar to HT942524NFRPCTA

Incumbent or Similar Grants

Grants similar to HT942524NFRPCTA

Similar Active Opportunities

Open grant opportunities similar to HT942524NFRPCTA